Suppr超能文献

依替膦酸对预防骨水泥型髋关节置换术后假体周围骨丢失的作用:一项随机、双盲、对照试验。

Effect of etidronate in preventing periprosthetic bone loss following cemented hip arthroplasty: a randomized, double blind, controlled trial.

作者信息

Fokter Samo K, Komadina Radko, Repse-Fokter Alenka

机构信息

Department of Orthopedic Surgery and Sports Trauma, Celje General Hospital, Oblakova 5, 3000 Celje, Slovenia.

出版信息

Wien Klin Wochenschr. 2006;118 Suppl 2:23-8. doi: 10.1007/s00508-006-0556-7.

Abstract

INTRODUCTION

Periprosthetic bone loss occurs after insertion of a total hip prosthesis and is often a result of stress shielding or altered loading of the proximal femur. Preventing the bone loss, which may threaten the prosthesis survival, with an antiresorptive drug would be highly advantageous.

MATERIALS AND METHODS

Our study investigated the effect of cyclic etidronate therapy on periprosthetic, contralateral hip, and spine bone mineral density (BMD) in a one-year, prospective, randomized, double-blind study in 31 patients after cemented hip arthroplasty. Etidronate was taken orally in a regimen repeated every 14 weeks, and periprosthetic BMD was measured with dual energy X-ray absorptiometry (DXA) in the total periprosthetic area and in the seven Gruen zones at 1 week (baseline), 6 weeks, 3 months, 6 months, and 12 months postoperatively.

RESULTS

In the etidronate group there were significant temporal BMD decreases measured in Gruen zones 2, 3, 6, and 7 and in the entire proximal femur; the greatest decrease was 12.9% and was measured in zone 7 at six months. Also in the etidronate group, there was a significant 2.8% temporal BMD increase in the spine at 12 months. In the placebo group there were significant temporal BMD decreases measured in Gruen zones 1, 2, 3, 5, 6, and 7 and in the entire proximal femur; the greatest decrease was 25.5% and was measured in zone 7 at 12 months. There were no significant differences between the mean BMD measurements of the etidronate and placebo groups.

CONCLUSION

These findings suggest that cyclic etidronate therapy has no significant effect in suppressing periprosthetic bone loss after cemented hip arthroplasty.

摘要

引言

全髋关节假体植入后会发生假体周围骨丢失,这通常是应力遮挡或股骨近端负荷改变的结果。使用抗吸收药物预防可能威胁假体存活的骨丢失将非常有益。

材料与方法

我们的研究在31例接受骨水泥型髋关节置换术的患者中进行了一项为期一年的前瞻性、随机、双盲研究,调查了周期性依替膦酸治疗对假体周围、对侧髋关节和脊柱骨密度(BMD)的影响。依替膦酸采用每14周重复一次的方案口服,术后1周(基线)、6周、3个月、6个月和12个月时,使用双能X线吸收法(DXA)在整个假体周围区域和七个Gruen区测量假体周围骨密度。

结果

在依替膦酸组中,Gruen区2、3、6和7以及整个股骨近端的骨密度随时间显著下降;最大降幅为12.9%,在6个月时于7区测得。同样在依替膦酸组中,12个月时脊柱骨密度随时间显著增加2.8%。在安慰剂组中,Gruen区1、2、3、5、6和7以及整个股骨近端的骨密度随时间显著下降;最大降幅为25.5%,在12个月时于7区测得。依替膦酸组和安慰剂组的平均骨密度测量值之间无显著差异。

结论

这些发现表明,周期性依替膦酸治疗在抑制骨水泥型髋关节置换术后假体周围骨丢失方面没有显著效果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验